PVC & HEART FAILURE THERAPEUTIC OPTIONS AND NOVEL APPROACHES - - PowerPoint PPT Presentation

▶
pvc
SMART_READER_LITE
LIVE PREVIEW

PVC & HEART FAILURE THERAPEUTIC OPTIONS AND NOVEL APPROACHES - - PowerPoint PPT Presentation

Sep 05, 2022 205 likes •694 views

PVC & HEART FAILURE THERAPEUTIC OPTIONS AND NOVEL APPROACHES Alireza Ghorbani Sharif, MD Electrophysiologist Tehran arrhythmia Clinic May 2016 DEFINITION Premature ventricular contractions (PVCs) are early depolarization of the

slide-1
SLIDE 1

PVC

& HEART FAILURE

THERAPEUTIC OPTIONS AND NOVEL APPROACHES Alireza Ghorbani Sharif, MD

Electrophysiologist

Tehran arrhythmia Clinic

May 2016

slide-2
SLIDE 2

DEFINITION

  • Premature ventricular contractions (PVCs) are early

depolarization of the myocardium originating in the ventricle.

  • Traditionally they have been thought to be relatively

benign in the absence of structural heart disease.

Yong-Mei Cha, MD; Glenn K. Lee, MBBS; Kyle W. Klarich, MD; Martha Grogan, MD, (Circ Arrhythm Electrophysiol. 2012;5:229-236.)

slide-3
SLIDE 3

PVCS

Compensatory Pause Interpolated PVCs

slide-4
SLIDE 4

ETIOLOGY

  • Causes:
  • Hypoxia
  • Myocardial Ischemia
  • Electrolyte Imbalance
  • Digitalis Toxicity
  • Congestive Heat Failure or CHF
  • Idiopathic
slide-5
SLIDE 5

PVCS AND VENTRICULAR TACHYCARDIA

slide-6
SLIDE 6

EPIDEMIOLOGY

  • PVCs are common with an estimated prevalence of 1% to

4% in the general population.

  • In a normal healthy population PVCs have been detected in

1% of subjects on standard 12-lead electrocardiography and between 40% and 75% of subjects on 24- to 48-hour Holter monitoring.

  • Their prevalence is generally age-dependent ranging from

1% in children 11 years 7 to 69% in subjects 75 years.

Yong-Mei Cha, MD; Glenn K. Lee, MBBS; Kyle W. Klarich, MD; Martha Grogan, MD, (Circ Arrhythm Electrophysiol. 2012;5:229-236.)

slide-7
SLIDE 7

PVC-INDUCED CARDIOMYOPATHY (PVCI-CMP)

  • Commonly thought to be a benign entity the concept of PVC-

induced cardiomyopathy was proposed by Duffee et a in 1998 when pharmacological suppression of PVCs in patients with presumed idiopathic dilated cardiomyopathy subsequently improved left ventricular (LV) systolic dysfunction.

  • It was only15 years ago that the term of (PVCi-CMP) emerged.

Yong-Mei Cha, MD; Glenn K. Lee, MBBS; Kyle W. Klarich, MD; Martha Grogan, MD, (Circ Arrhythm Electrophysioloy. 2012;5:229-236.) Marie Sadron Blaye- Felice,MD et al, (Heart Rhythm2016;13:103–110)

slide-8
SLIDE 8

MECHANISMS AND PATHOPHYSIOLOGY

Yong-Mei Cha, Circ Arrhythm Electrophysiol. 2012;5:229-236.

slide-9
SLIDE 9

WHICH CAME FIRST THE CHICKEN OR THE EGG?

slide-10
SLIDE 10

CLINICAL EVALUATION

  • Because a single 24-hour recording may not reflect the true PVC load due to day-to-day

variability, a strong suspicion that frequent PVCs may be the cause of LV dysfunction may warrant extended Holter recordings of 48 to 72 hours or several 24-hour Holter recordings.

  • Echocardiographic features in PVC-induced cardiomyopathy include decreased LVEF,

increased LV systolic and diastolic dimensions, wall motion abnormalities, which are

  • ften global as opposed to regional as well as mitral regurgitation (typically due to mitral

annular dilatation)

  • Two-dimensional speckle tracking strain imaging detect subtle changes in the ventricles

function whereas the LVEF remains preserved.

Yong-Mei Cha, MD; Glenn K. Lee, MBBS; Kyle W. Klarich, MD; Martha Grogan, MD, (Circ Arrhythm Electrophysiol. 2012;5:229-236.)

slide-11
SLIDE 11

CLINICAL EVALUATION

  • Coronary angiography should be performed in every patient with

reduced LV systolic function to exclude significant coronary artery disease except for those with a low cardiovascular risk.

  • Cardiac MRI may be warranted in detecting arrhythmogenic right

ventricular cardiomyopathy with LV involvement and infiltrative disease when clinically suspected.

Yong-Mei Cha, MD; Glenn K. Lee, MBBS; Kyle W. Klarich, MD; Martha Grogan, MD, (Circ Arrhythm Electrophysiol. 2012;5:229-236.)

slide-12
SLIDE 12

PARAMETERS SIGNIFICANTLY RELATED TO THE PVCI-CMP

  • 1. PVC burden
  • 2. Symptoms : Presence or absence of palpitation
  • 3. Duration of symptoms
  • 4. Age and gender
  • 5. Morphology and Sit of origin

Marie Sadron Blaye-Felice, MD, (Heart Rhythm2016;13:103–110)

slide-13
SLIDE 13

PVCS BURDEN

  • Majority of patients with frequent PVCs have a benign course

whereas up to one third of them develop PVCi-CMP.

  • The prevalence of PVCi-CMP is estimated as only 5% to 7%

among patients with a PVC burden 10%.

  • Baman and Fred Morady et al suggested that a PVC burden of

24% had a sensitivity and specificity of approximately 80% in separating the patient populations with impaired versus preserved LV function.

Yong-Mei Cha, MD; Glenn K. Lee, MBBS; Kyle W. Klarich, MD; Martha Grogan, MD, (Circ Arrhythm Electrophysiol. 2012;5:229-236.) Timir S. Baman, MD, Fred Morady et al, (Heart Rhythm 2010;7:865–869)

slide-14
SLIDE 14

PVCS BURDEN

  • Takemoto et al analyzed the result of ablation with relation to 3 pre

specified subgroups (<10%,10%–20%, >20%) based on the burden of PVCs on 24-hour Holter monitoring the subgroup with >20% of PVCs at baseline had the most benefit from ablation with significant improvement in LVEF and LV dimensions

  • When the PVC burden was expressed in the absolute number of PVCs

before RFA, the subgroup with >20 000 PVCs per day was shown to be associated with highest risk of LV dysfunction and heart failure.

  • Clin. Cardiol. 38, 4, 251–258 (2015) A. Saurav et al: PVC-induced cardiomyopathy
slide-15
SLIDE 15

SYMPTOMS AGE AND GENDER

  • Absence of symptoms are independently associated with PVCi-

CMP because diagnosis of PVCs is delayed in asymptomatic patients

  • ften made fortuitously over the course of the developing CMP
  • The duration of palpitations of 30 to 60 months specially more

than 60 months

  • More common with increasing age and in males

Marie Sadron Blaye- Felice, MD, (Heart Rhythm2016;13:103–110) Fred Morady , MD, et al ,Heart Rhythm 2012;9:92–95

slide-16
SLIDE 16

MORPHOLOGY AND SITE OF ORIGIN

  • Long PVC-QRS duration
  • Epicardial origin of the focus
  • Interpolated PVCs
  • LV origin of PVCs
  • Long PVC coupling interval
  • High PVC QRS amplitude
  • Presence of polymorphic PVCs
slide-17
SLIDE 17

MORPHOLOGY AND SITE OF ORIGIN

  • Longer PVC-QRS duration, especially in the presence of a LBBB

participate in the alteration of LV function because of the electrical and therefore likely associated mechanical dyssynchrony.

  • Epicardial PVCs have longer PVC-QRS duration than other PVCs

probably because of the paucity of Purkinje fibers in the epicardium.

Marie Sadron Blaye- Felice, MD, (Heart Rhythm2016;13:103–110)

slide-18
SLIDE 18

EPICARDIAL PVCS

slide-19
SLIDE 19

MORPHOLOGY AND SITE OF ORIGIN

  • Interpolated PVCs have a longer Ventriculo-atrial block

cycle length compared with PVCs without interpolation.

  • The total PVC burden increased with interpolation
  • Clin. Cardiol. 38, 4, 251–258 (2015) A. Saurav et al: PVC-induced cardiomyopathy
slide-20
SLIDE 20

INTERPOLATED PVCS

  • Clin. Cardiol. 38, 4, 251–258 (2015) A. Saurav et al: PVC-induced cardiomyopathy
slide-21
SLIDE 21

MORPHOLOGY AND SITE OF ORIGIN

LV origin of PVCs Long PVC coupling interval High PVC QRS amplitude Presence of polymorphic PVCs

Marie Sadron Blaye-Felice, MD, (Heart Rhythm2016;13:103–110) Fred Morady, MD et al, (Heart Rhythm 2011;8:1046 –1049)

slide-22
SLIDE 22

TREATMENT OPTIONS

  • Medical Therapy
  • Catheter Ablation
slide-23
SLIDE 23

MEDICAL THERAPY

  • Anti-Failure therapies
  • Typically, in mildly symptomatic patients with mild LV dysfunction a

trial of β-blockers or a nondihydropyridine calcium channel blocker should be considered as first-line therapy.

  • Class Ic and III antiarrhythmic agents such as flecainide and sotalol

are effective but with significant adverse effect.

  • These agents, with the exception of amiodarone, should not be used

in patients with sever LV dysfunction.

Fred Morady, MD et al, (Heart Rhythm 2011;8:1046 –1049)

slide-24
SLIDE 24

CATHETER ABLATION

  • There are growing evidence in favor of catheter ablation for PVCs especially in the

presence of LV dysfunction.

  • Multiple studies demonstrating high efficacy of catheter ablation of PVCs with success

rates ranging from 80% to 100%.

  • Procedural success may be dependent on the site of origin with lower efficacy for

epicardial foci or multiple PVC morphologies.

  • Major complications occur in approximately 3% of cases including death stroke

myocardial infarction cardiac perforation with or without pericardial tamponade pericardial effusion and blood vessel dissection or stenosis.

  • A. Saurav et al: PVC-induced cardiomyopathy Clin. Cardiol. 38, 4, 251–258 (2015)
slide-25
SLIDE 25

CATHETER ABLATION

  • In patients with frequent PVCs and PP-ICD indication

ablation improves LVEF and, in most cases, allows removal of the indication.

  • Withholding the ICD and reevaluating within 6 months
  • f ablation seems to be a safe and appropriate strategy

Ablation of frequent PVCs in patients meeting criteria for primary prevention ICD implant:

Heart Rhythm. 2015 Dec;12(12):2434-42. doi: 10.1016/j.hrthm.2015.09.011. Epub 2015 Sep 15.

slide-26
SLIDE 26
  • Sarrazin et al considered frequent PVCs to be 5% of the beats observed on a

24-hour monitor.

  • Our data suggest that despite the presence of scar tissue in post infarction

patients a component of reversible cardiomyopathy may be present in patients with frequent PVCs.

  • A low ejection fraction with a small amount of scar tissue may suggest a

potentially reversible cardiomyopathy.

Renee M. Sullivan, MD, Brian Olshansky, MD, FHRS doi:10.1016/j.hrthm.2009.08.029

CATHETER ABLATION

How many PVCs are too many in post-MI patients:

slide-27
SLIDE 27

PVC MEDIATED CARDIOMYOPATHY

  • Ablation of PVC in patient in presence of

structural heart disease

  • Reverse or stop of progression of LV dysfunction
slide-28
SLIDE 28

CATHETER ABLATION

  • Frequent PVCs to be 4-5% of the beats observed on a 24-hour monitor
  • In patients with frequent PVCs and nonischemic cardiomyopathy EF and

functional class can be improved but not always normalized by successful PVC ablation

Effect of ablation of in patients with nonischemic cardiomyopathy:

slide-29
SLIDE 29

EFFECTIVENESS OF ABLATION IN PVCI-CMP

  • The criterion for an effective ablation procedure was an 80%

reduction in the PVC burden.

  • Improved by at least 15% or normalized (ejection fraction 50%)

after an effective ablation procedure.

Timir S. Baman, MD, Fred Morady et al, (Heart Rhythm 2010;7:865–869)

slide-30
SLIDE 30

CONCLUSIONS

  • Frequent PVCs may be the consequence of LV systolic dysfunction
  • r the cause of LV dysfunction.
  • Reduction of frequent PVCs with antiarrhythmic drugs or by

ablation may improve LV function in patients presenting with newly recognized depressed LV function and frequent PVCs.

  • Catheter ablation appears to be more effective than antiarrhythmic

drugs in PVCs frequency reduction and LVEF normalization.

Li Zhong, MD, PhD et al Heart Rhythm2014;11:187–193

slide-31
SLIDE 31

CASE 1

  • 27 years old man with aborted SCD and previous ICD

implantation, LVEF 25%

  • Dyspnea
  • Palpitation
  • Frequent ventricular ectopies, progressive LV dysfunction and

possibility PVC induced cardiomyopathy

slide-32
SLIDE 32

PVCS

slide-33
SLIDE 33

EARLY SIGNAL

slide-34
SLIDE 34

EARLY SIGNAL

slide-35
SLIDE 35

TERMINATION OF PVCS DURING BURN

slide-36
SLIDE 36

LAO & RAO VIEWS

slide-37
SLIDE 37

3D MAPPING

slide-38
SLIDE 38

CASE 2

  • 65 years old man known case of DCM
  • Severe LV dysfunction( LVEF 20%)
  • Frequent PVC and ECG suggestive epicardial origin
slide-39
SLIDE 39

EARLY SIGNAL

slide-40
SLIDE 40

EARLY SIGNAL

slide-41
SLIDE 41

TERMINATION OF PVCS DURING BURN

slide-42
SLIDE 42

3D MAPPING

slide-43
SLIDE 43

3D MAPPING

slide-44
SLIDE 44

EPICARDIAL APPROACH

slide-45
SLIDE 45

EPICARDIAL APPROACH

slide-46
SLIDE 46

EPICARDIAL APPROACH

slide-47
SLIDE 47

Tehran Arrhythmia Center www.IranEP.org info@IranEP.org